Study Finds Angiogenic Inhibitor For Prostate cancer

Study Finds Angiogenic Inhibitor For Prostate cancer
Scientists from Bristol and Nottingham Universities have found that a single molecule plays a major role in the angiogenesis (formation of new blood vessels) of prostate cancer. The study “Serine–arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer” published in the Oncogene journal and led by Dr. Sebastian

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *